Welcome to the "Wegovy Magazine Israel" website, your comprehensive and scientific source of information. Behind the site stands Nordic Health Data ApS, a technology company from Denmark, specializing in making complex medical information accessible, clear, and useful.
Our company, located in Copenhagen, was established by a team of analysts and data researchers in the health field. We identified a significant gap between in-depth scientific research and the general public, which seeks reliable and clear information about innovative pharmacological treatments for obesity. Our goal is to bridge this gap.
Our worldview: Obesity is a medical condition, not a personal failure
For many decades, the discourse surrounding obesity has been rife with stigma and misconceptions. At Nordic Health Data, we approach the topic from a completely scientific perspective. We view obesity as a complex chronic disease, with metabolic and biological underpinnings, requiring medical attention and management based on solid evidence.
We established the site specifically for the Israeli audience, to provide direct access to the most up-to-date data on the drug "Wegovy" (Wegovy / Semaglutide 2.4mg). We focus on explaining the biological mechanisms of the drug, analyzing the results of leading clinical studies (such as the STEP research series), and presenting the accepted medical protocols in Israel and Europe.
Our approach: Facts before opinions
Unlike websites offering "diet tips," our content is built on an analytical and systematic methodology, based on three fundamental principles:
- In-depth analysis of clinical studies: We dive into the official data from the clinical trials conducted on the drug and present you with the complete and statistical picture: What was the average percentage of weight loss? Over what period? What were the most common side effects and how frequently did they occur?
- Continuous regulatory monitoring: We continuously monitor the publications and guidelines from the major regulatory bodies worldwide – the US FDA, the European EMA, and of course, the Israeli Ministry of Health. Any change in indications, safety warnings, or usage guidelines is updated on the site in real-time.
- Complete transparency of data: We believe that every patient deserves the right to receive the whole truth, even when it is complex. Therefore, we clearly present the differences between Wegovy and Ozempic, the realistic chances of success as indicated by the studies, and the potential risks associated with treatment.
Independence and compliance with Israeli law
The site is intended for a Hebrew-speaking audience and operates in full compliance with the laws in Israel:
- We are not a marketing entity: The site serves as a passive source of information only. It does not advertise or encourage the use of medications. Its purpose is to enrich the knowledge of patients who have already received a medical recommendation and are in the process of consulting with a doctor.
- Complete separation from commerce: Nordic Health Data ApS is an entirely independent information entity. We do not engage in the sale of medications. It is not possible to order weight loss injections, obtain prescriptions, or conduct any type of financial transaction through the site.
- Objectivity and full independence: We have no business relationship with the drug manufacturer (Novo Nordisk). The coverage on the site is objective, not funded by any entity in the pharmaceutical industry, and is based solely on scientific data.
Our commitment to accuracy
All content published on the site undergoes a rigorous quality control (QA) process. Editors with backgrounds in life sciences check every data point, dosage, or guideline to ensure that the information presented is accurate, reliable, and consistent with the latest professional literature.
Limits of responsibility: The information is a tool, not a substitute for a doctor
The data and analyses presented on the site are intended for enrichment and education only.
- This information should not be considered a substitute for personal and professional medical advice.
- Statistical data from studies do not guarantee personal outcomes; the body's response to pharmacological treatment is individual and varies from person to person.
- The decision to start treatment with Wegovy must be made only after an in-depth discussion with a specialist doctor, taking into account your complete medical history.
We are here to enrich your knowledge
We invite you to use the site as a tool for better understanding of the treatment. If you encounter information that you believe requires clarification, updating, or correction, we would appreciate it if you contact our data department.
Contact address: [email protected]
Company offices:
Nordic Health Data ApS
Vesterbrogade 149, 1620 Copenhagen, Denmark